Myelo-ablative therapy with peripheral blood progenitor cell (PBPC support in patients with haematological malignancy

Pigaditou, Anna; Marini, G; Johnson, Peter; Mahmoud, Matti; Okukenu, E.; Adams, K. R.; Salam, Ashiq; Amess, J. A. L.; Norton, A. J.; Murphy, M. F.; Carter, M.; Dale, Christopher; Malpas, J. S.; Lister, T. A.; Rohatiner, A. Z. S.

doi:10.1093/oxfordjournals.annonc.a059042

Cited by 8 publications

(1 citation statement)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2 Overall survival and duration of remission sequently received 1 g/m 2 ara-C bd for 6 days and whole body irradiation, 200 cGy!6 fractions, followed by reinfusion of the treated marrow. More recently, in the two other patients, an attempt was made to collect Ph-negative peripheral blood progenitor cells mobilised as previously described [13]. Unfortunately, adequate numbers of cells having been collected in both patients, cytogenetic analysis revealed Ph-positive cells in the collection and the myeloablative therapy was therefore not given.…”

Section: Treatmentmentioning

confidence: 99%

Intensive chemotherapy for adult acute lymphoblastic leukaemia given with or without granulocyte-macrophage colony stimulating factor

Papamichael

Andrews

Owen

et al. 1996

Annals of Hematology

Self Cite

View full text Add to dashboard Cite

Twenty-six patients with newly diagnosed ALL (age range 15-49 years, median 32 years) received treatment comprising: cycles 1 and 2: adriamycin 30 mg/m2 days 1-3, vincristine: 2 mg days 1, 8, and 15, with prednisolone 40 mg daily, given until complete remission (CR). L-asparaginase 10000 units/m2, days 1-14, was given only with the first cycle. Cycle 3 consisted of 100 mg/m2 etoposide orally, days 1-5, and 1 gm/m2 bd cytosine arabinoside (ara-C) days 1-5. Cycles 1-3 were then repeated. Intrathecal methotrexate (MTX) 12.5 mg was given on day 1 of each treatment cycle. The first 12 consecutive patients received this chemotherapy alone, the subsequent 14 received, in addition, 3 micrograms/kg GM-CSF subcutaneously, from day 4 of cycles 1,2,4 and 5 (and from day 6 of cycles 3 and 6) until the absolute neutrophil count had reached 0.5 x 10(9)/1. All patients in whom CR was achieved then received prophylactic cranial irradiation. With the exception of those with T-ALL, this was followed by oral maintenance therapy consisting of 6-mercaptopurine, MTX, and cyclophosphamide for 3 years. Patients receiving GM-CSF did not have shorter intercycle times or a lower incidence of documented infections than those who did not receive it. The CR rate was 89% overall-uninfluenced by GM-CSF, but higher than that achieved previously at St Bartholomew's Hospital in an equivalent age-group.

show abstract

Section: Treatmentmentioning

confidence: 99%